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Abstract
Background: Microglia, the immunocompetent cells of the CNS, rapidly respond to brain injury and disease by
altering their morphology and phenotype to adopt an activated state. Microglia can exist broadly between two
different states, namely the classical (M1) and the alternative (M2) phenotype. The first is characterized by the
production of pro-inflammatory cytokines/chemokines and reactive oxygen and/or nitrogen species. In contrast,
alternatively activated microglia are typified by an anti-inflammatory phenotype supporting wound healing and
debris clearance. The objective of the present study was to determine the outcome of lysophosphatidic acid
(LPA)-mediated signaling events on microglia polarization.
Methods: LPA receptor expression and cyto-/chemokine mRNA levels in BV-2 and primary murine microglia (PMM)
were determined by qPCR. M1/M2 marker expression was analyzed by Western blotting, immunofluorescence
microscopy, or flow cytometry. Cyto-/chemokine secretion was quantitated by ELISA.
Results: BV-2 cells express LPA receptor 2 (LPA2), 3, 5, and 6, whereas PMM express LPA1, 2, 4, 5, and 6. We show
that LPA treatment of BV-2 and PMM leads to a shift towards a pro-inflammatory M1-like phenotype. LPA treatment
increased CD40 and CD86 (M1 markers) and reduced CD206 (M2 marker) expression. LPA increased inducible nitric
oxide synthase (iNOS) and COX-2 levels (both M1), while the M2 marker Arginase-1 was suppressed in BV-2 cells.
Immunofluorescence studies (iNOS, COX-2, Arginase-1, and RELMα) extended these findings to PMM. Upregulation
of M1 markers in BV-2 and PMM was accompanied by increased cyto-/chemokine transcription and secretion
(IL-1β, TNFα, IL-6, CCL5, and CXCL2). The pharmacological LPA5 antagonist TCLPA5 blunted most of these
pro-inflammatory responses.
Conclusions: LPA drives BV-2 and PMM towards a pro-inflammatory M1-like phenotype. Suppression by TCLPA5
indicates that the LPA/LPA5 signaling axis could represent a potential pharmacological target to interfere with
microglia polarization in disease.
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(palmitoyloxy)butyl-phosphonate; CXCL2, C-X-C motif chemokine 2; CCL4, C-C motif chemokine 4; CCL5, C-C motif
chemokine 5; CNS, Central nervous system; COX-2, Cyclooxygenase 2; DCFDA, 2′,7′-dichlorofluorescin diacetate;
DMSO, Dimethylsulfoxide; IL-1β, Interleukin-1β; IL-6, Interleukin-6; iNOS, Inducible nitric oxide synthase;
LPA, Lysophosphatidic acid; LPA1-6, LPA receptors 1-6; MRC1, Macrophage mannose receptor 1; ONOO−, Peroxynitrite;
o/n, Overnight; PE, Phycoerythrin; PMM, Primary murine microglia; qPCR, Quantitative real-time PCR; RELMa, Resistin-like
alpha; ROS, Reactive oxygen species; TBHP, tert-Butylhydroperoxide; TCLPA5, 5-(3-Chloro-4-cyclohexylphenyl)-1-(3-
methoxyphenyl)-1H-pyrazole-3-carboxylic acid; TNFα, Tumor necrosis factor α
Background
Microglia are the resident immune cells of the brain and
are endowed with specific receptor sets that are able to
detect subtle alterations of the finely tuned micromilieu
in the central nervous system (CNS) [1, 2]. Even in the
resting state, the dynamic microglia processes scan the
CNS environment and respond to danger signals [3].
Neuronal injury results in the release of ATP, neuro-
transmitters, growth factors and cytokines, or in changes
of local ion homeostasis resulting in microglia activation
[4]. Depending on the signal encountered, microglia can
activate different repair programs that determine the se-
verity of the response [4]. These responses include mor-
phological transformation (increased size of cell bodies,
thickening of proximal processes, decreased ramification
of distal branches), proliferation, migration, phagocyt-
osis, and the production of bioactive molecules [5].
These events are presumably the first steps that mobilize
the cellular and molecular defense machinery in the
CNS leading to subsequent microglia activation. De-
pending on the environmental milieu and stimulus en-
countered, this activation profile of microglia can reach
from classically activated (M1) to alternatively activated
(M2) cells [6].
Lysophosphatidic acid (LPA) is a mixture of saturated
or unsaturated acyl/alkyl residues at the sn-1 or sn-2
position [7] that are present in biological fluids including
cerebrospinal fluid (CSF) [8]. LPA is produced through
different pathways by means of phospholipase A1- and
A2-mediated hydrolysis of phosphatidic acid [8], de novo
synthesis from glycerol-3-phosphate via acyltransferases
[9], or autotaxin (ATX)-dependent cleavage of lysopho-
sphatidylcholine [10]. The majority of circulating LPA is
thought to originate from ATX [11]. In line, LPA levels
in mice heterozygous for the ATX allele are reduced by
50 % [12–14]. Tissue distribution analyses revealed that
ATX is expressed in murine and human brain [15]. Con-
sistently, the brain contains significant levels of LPA
[16], which increase in response to CNS injury [17–19].
In vitro and in vivo data demonstrated that LPA
receptor-mediated signaling cascades play prominent
roles in the CNS [20, 21].
The effects of LPA are mediated through the six cur-
rently recognized G protein-coupled receptors termed
LPA receptors 1-6 (LPA1-6), which couple to one or
more heterotrimeric G proteins [21, 22]. All members of
the LPA receptor family are expressed in the CNS and
regulate blood-brain barrier permeability [23], neuropro-
genitor cell function [24], synaptic transmission [25],
myelination [26], and brain immune responses [27–29].
Microglia express a range of LPA receptors that regulate
cell morphology [30], membrane ruffling and hyperpo-
larization [31], metabolic changes [27], migration and
ion mobilization [29], and growth factor production
[31]. Recently, it was demonstrated that activation of
LPA1 contributes to demyelination in spinal cord injury
and that these effects are partly mediated by activated
microglia [19].
In the peripheral immune system, LPA may adopt the
role of sphingosine-1-phosphate during lymphocyte
egress [32]. ATX is expressed in lymphoid organ high
endothelial venules, where it generates LPA and pro-
motes the entry of lymphocytes into lymphoid organs
[33, 34]. It was suggested that local synthesis of LPA by
ATX provides a chemotactic signal that facilitates T cell
exit from the circulation into the lymph nodes [35]. In
accordance, 1-bromo-3(S)-hydroxy-4-(palmitoyloxy)bu-
tyl]phosphonate (BrP-LPA), which antagonizes ATX and
LPA receptor function, attenuated trafficking of lympho-
cytes into lymph nodes [36]. LPA potently affects migra-
tion, chemotaxis, proliferation, survival signaling, and
interleukin-1β (IL-1β) secretion in different cell types of
the immune system (reviewed in [35]). In monocyte-
derived dendritic cells, LPA upregulates expression of
CD86 (M1 marker), thereby enhancing T cell prolifera-
tion [37].
Unlike other CNS resident cells, microglia originate
from hematopoietic stem cells in the yolk sac and act as
primary cells responding to pathogens or injuries of the
CNS. Similarly to macrophages, microglia polarize to an
M1 phenotype (e.g. in response to lipopolysaccharide;
LPS) in order to produce pro-inflammatory mediators
[38]. In contrast, the anti-inflammatory cytokine IL-4
gives rise to the formation of a protective M2 microglia
population in a murine stroke model [39]. Based on this
evidence, it is conceivable that mediators controlling
M1/M2 polarization of microglia could impact on pro-
motion or resolution of neuroinflammation in the CNS.
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In earlier studies, we showed that LPA increases the
expression of several glycolytic enzymes in microglia
[27], indicating a shift towards a pro-inflammatory M1
polarization [40]. We suggest that LPA may act as a po-




Cell culture medium RPMI1640 and DMEM (Dulbecco’s
modified Eagle’s medium), fetal calf serum (FCS), antibi-
otics, and 0.25 % trypsin were from Invitrogen (Waltham,
MA, USA). LPA (1-oleoyl-2-hydroxy-sn-glycero-3-phos-
phate) was from Sigma-Aldrich (St. Louis, MO, USA). Re-
combinant murine IL-4 and IL-10 were from Peprotech
(Rocky Hill, NJ, USA) and LPS from E. coli (O111:B4) was
from Sigma-Aldrich (St. Louis, MO, USA). Antibodies
against cyclooxygenase 2 (COX-2) and arginase-1 (Arg-1;
used only for Western blotting) were purchased from Cell
Signaling (Beverly, MA, USA), inducible nitric oxide syn-
thase (iNOS) antibody was from BD Biosciences (San Jose,
CA, USA). For immunofluorescence, the COX-2 and Arg-
1 antibodies were from Santa Cruz (Dallas, TX, USA), the
antibodies against resistin-like alpha (RELMα, alternative
name FIZZ-1) and iNOS were from Abcam (Cambridge,
UK) and the CD11b antibody was from Novus Biologicals
(Littleton, CO, USA). β-Tubulin monoclonal antibody, β-
actin and tomato-lectin were from Sigma-Aldrich (St.
Louis, MO, USA). Alexa Fluor® 488 Phalloidin was from
Invitrogen (Waltham, MA, USA). Phycoerythrin (PE)-
CD40, allophycocyanin (APC)-CD86, PE-CD206 anti-
bodies and their isotype controls were from e-Bioscience
(San Diego, CA, USA). 5-(3-Chloro-4-cyclohexylphenyl)-
1-(3-methoxyphenyl)-1H-pyrazole-3-carboxylic acid
(TCLPA5) was from Tocris Bioscience (Bristol, UK)
and BrP-LPA was from Echelon Biosciences (Salt Lake
City, UT, USA). tert-Butyl hydroperoxide was from
Sigma-Aldrich. ELISA development kits were from
Peprotech (Rocky Hill, NJ, USA). Primers were from QIA-
GEN or Invitrogen. Kits that were used for quantitative
real-time PCR (qPCR) analysis were purchased from QIA-
GEN (Hilden, Germany) or Applied Biosystems (Foster
City, CA, USA).
BV-2 microglia
The BV-2 murine microglial cell line was purchased
from Banca Biologica e Cell Factory (Genova, Italy).
Cells were grown and maintained in RPMI1640 medium
supplemented with 10 % FCS, 1 % penicillin/strepto-
mycin, and 1 % glutamine and cultured under standard
conditions. Culture medium was changed to fresh
medium every 2 or 3 days and when the cells reached
confluence, they were splitted into new flasks or used
immediately for the experiments.
Primary microglia isolation and culture
Primary murine microglia (PMM) were isolated and
purified from cortices of neonatal (P0–P4) mice as previ-
ously described [41]. In brief, cortices were isolated from
the whole brain, stripped from their meninges, and
minced into small pieces. Glial cells were separated by
trypsinization (0.1 % trypsin, 20 min, 37 °C, 5 % CO2),
and the cell suspension was cultured in 75 cm2 tissue
culture flasks precoated with 5 mg/ml poly-D-lysine in
DMEM containing 15 % FCS, 1 % penicillin/strepto-
mycin, and 1 % glutamine. After 2 to 3 days in culture,
the medium was changed to DMEM/10 % FCS and cells
were cultured for additional 10 to 14 days. Microglia
were removed from the astrocytic monolayer by smack-
ing the flasks 10-20 times and seeded onto poly-D-ly-
sine-coated cell culture plates for further use. The purity
of primary murine microglia was determined by im-
munocytochemistry with anti-CD11b or tomato-lectin
staining and was always ≥95 %.
qPCR analysis
Total RNA was extracted from BV-2 or primary microglia
cells using the RNeasy Mini or RNeasy Micro kit (QIA-
GEN, Hilden, Germany) and quantified using NanoDrop
(Thermo Fisher Scientific, Waltham, MA, USA). RNA
was reverse-transcribed by using the high-capacity cDNA
reverse transcription kit (Applied Biosystems, Foster City,
CA, USA) or by using the SuperScript® III reverse tran-
scription kit (Invitrogen, Waltham, MA, USA). Quantita-
tive real-time PCR (qPCR) was performed on an Applied
Biosystems 7900HT Fast Real-Time PCR System using the
QuantifastTM SYBR® Green PCR kit (QIAGEN, Hilden,
Germany). Amplification of murine hypoxanthine-
guanine phosphoribosyltransferase (HPRT) as housekeep-
ing gene was performed on all samples as internal controls
to account for variations in mRNA levels. Expression pro-
files and associated statistical parameters were analyzed by
the 2-ddCt method [42]. Gene specific primers were pur-
chased from QIAGEN (LPA receptors) and Invitrogen (cy-
tokines and chemokines). Primer sequences are listed in
Tables 1 and 2. In case of non-detects, we discriminate be-
tween undetermined values (that do not exceed the Ct
threshold) and absent values (no reaction occurred) [43].
LPA treatment
For LPA treatment, BV-2 and PMM were plated in poly-
D-lysine precoated plates (different sizes according to
each experiment) and allowed to adhere for 2–3 days.
Before treatments, cells were always incubated in serum-
free DMEM overnight (o/n). The following day, medium
was changed to serum-free DMEM containing 0.1 %
BSA (control) or DMEM containing 0.1 % BSA and LPA
(1 μM). BSA was used as LPA carrier. Aqueous LPA
stock solutions (10 mM) were stored at −70 °C. Only
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freshly thawed stock solutions were used for the experi-
ments. LPA solutions, culture medium, BSA, and PBS
that were used during the experiments were tested for
endotoxin content using the Limulus amebocyte lysate
test. Endotoxin content was always <0.5 EU/ml.
Pharmacological inhibition of LPA receptors
We used BrP-LPA, a pan LPA receptor/ATX antagonist
[44] and TCLPA5, a specific antagonist for LPA5 [45].
BrP-LPA was diluted in distilled water (stock concentra-
tion of 2 mM), aliquoted and kept at −20 °C. TCLPA5
was diluted in dimethylsulfoxide (DMSO) (stock concen-
tration 100 mM) and kept at −20 °C. TCLPA5 solutions
are stated to be stable for maximum 40 days. During the
experiments, both antagonists were used at a final con-
centration of 5 μM. Cells were pretreated with the an-
tagonists for 2 h before starting the experiment.
Immunoblotting
For Western blotting experiments, BV-2 cells were seeded
onto 6-well plates at a density of 1 × 105 cells/well. Prior
to experiments, cells were cultured in serum-free medium
(o/n) and then incubated in serum-free medium contain-
ing 0.1 % BSA in the presence of 1 μM LPA or 1 μM LPA
in the absence or presence of BrP-LPA (5 μM) or TCLPA5
(5 μM) for the indicated time periods. After removing the
supernatant, cells were washed twice with ice-cold PBS
and lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 1 %
NP-40, 150 mM NaCl, 1 mM Na3VO4, 1 mM NaF, 1 mM
EDTA) containing protease inhibitors (aprotinin, leupep-
tin, pepstatin: 1 μg/ml each), 10 μM PMSF, and phosphat-
ase inhibitors (Thermo Scientific, Vienna, Austria). Cells
were mechanically scraped off using a rubber scraper and
centrifuged at 13,000 rpm for 10 min. Protein concentra-
tions were determined using the BCA kit (Thermo Scien-
tific) using BSA as a standard. One hundred micrograms
of total cell protein was loaded per lane and separated by
SDS-PAGE (10 %). After electrophoresis, proteins were
transferred to polyvinylidene difluoride membranes using
electrophoretic transfer (Bio-Rad, Berkeley, CA, USA).
Membranes were blocked with 5 % low-fat milk in TBST
for 2 h at room temperature and incubated with the fol-
lowing primary antibodies: anti-iNOS (1:500), anti-Arg-1
(1:1000), and anti-COX-2 (1:1000). After removal of pri-
mary antibodies, the membranes were washed for 30 min
in TBST and incubated for 2 h at room temperature with
HRP-conjugated secondary antibodies (anti-rabbit
1:10,000; anti-mouse 1:5000). After washing with TBST
for 1 h, immunoreactive bands were visualized using ECL
or ECL plus reagents (Thermo Scientific) and detected
with a chemiluminescence detection system (ChemiDoc
Bio-Rad, Berkeley, CA, USA).
Immunofluorescence
To examine changes in cell morphology in response to
LPA treatment, BV-2 and primary microglia were
stained for β-tubulin or F-actin. After seeding, cells were
serum-starved (untreated) or incubated in the presence
of 1 μM LPA (24 h). Then, cells were washed with pre-
warmed PBS, fixed with 4 % paraformaldehyde/PBS for
10 min, and permeabilized with 0.5 % TritonX/PBS for
10 min at room temperature. Following washing with
PBS, cells were incubated with blocking buffer (Thermo
Scientific, Waltham, MA, USA) for 1 h at 4 °C. Incuba-
tions with anti-β-tubulin (1:100) or phalloidin (1:50)
were carried out overnight at 4 °C. Finally, cells stained
for β-tubulin were incubated with cyanine (Cy)-3-labeled
secondary antibody (1:200, 30 min, room temperature).
Microglia nuclei were counterstained with Hoechst
33342 (Invitrogen, Waltham, MA, USA). All slides were
washed three times with PBS and mounted using a
mounting medium (Dako Austria GmbH, Vienna,
Austria).
To identify changes in M1 and M2 markers, BV-2 and
PMM were seeded onto poly-D-lysine-coated chamber
slides at a density of 4 × 104 and 1 × 105 cells, respectively,
and incubated in serum-free medium in the absence or
Table 2 Primers (Invitrogen) used for expression analyses of cytokines and chemokines by qPCR
Gene Forward primer (5′–3′) Reverse primer (5′–3′) Product length (bp)
Ccl5 GCTGCTTTGCCTACCTCTCC TCGAGTGACAAACACGACTGC 104
Cxcl2 AGTGAACTGCGCTGTCAATG GCCCTTGAGAGTGGCTATGA 126
Il1β TGTGAAATGCCACCTTTTGA GGTCAAAGGTTTGGAAGCAG 94
Il6 TGATGCACTTGCAGAAAACA ACCAGAGGAAATTTTCAATAGGC 109
Tnfα CCACCACGCTCTTCTGTCTAC AGGGTCTGGGCCATAGAACT 103
Table 1 Primers (QIAGEN) used for qPCR analyses of LPA
receptor expression
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presence of LPA (1 μM) or LPA plus TCLPA5 (5 μM).
LPS (20 ng/ml) and IL-4 (40 ng/ml) were used as positive
controls for M1 and M2 polarization of PMM. Fixation,
permeabilization, and blocking steps were performed as
described above. Following blocking of unspecific binding,
cells were incubated with FITC-conjugated tomato lectin
(1:100) and antibodies against iNOS (1:20), Arg-1 (1:50),
COX-2 (1:20), or RELMα (1:50), followed by incubation
with labeled secondary antibodies. Slides were counter-
stained with Hoechst 33342. Confocal fluorescence mi-
croscopy imaging was performed using a Leitz/Leica
TCSSP2 microscope (Leica Lasertechnik GmbH, Heidel-
berg, Germany). Quantification of fluorescence intensity
was performed using ImageJ. At least 50 cells out of 3 dif-
ferent areas per chamber were measured.
Flow cytometry
Flow cytometry was used in order to assess the expres-
sion of CD40, CD86, and CD206 in microglia cells. BV-2
and PMM were seeded in triplicate onto 6-well and
poly-D-lysine coated 24-well plates at a density of 1 × 105
and 1.5 × 105 cells per well, respectively. After 24 h
serum starvation, cells were incubated in the presence of
1 μM LPA for 12, 24, and 48 h. BV-2 cells were also
used to test effects of the inhibitors on surface marker
expression. Serum-starved cells were incubated with ve-
hicle controls, LPA, or LPA plus the antagonists for the
abovementioned time periods. Cells were then collected,
blocked using the Ultra V blocker (Thermo Scientific),
and incubated with PE anti-CD40, APC anti-CD86, or
PE anti-CD206 antibody (1:50). Finally, cells were fixed
and measured using a Guava easyCyte 8 Millipore flow
cytometer.
ELISA
IL-1β, tumor necrosis factor α (TNFα), interleukin-6
(IL-6), CCL5 (RANTES), and C-X-C motif chemokine 2
(CXCL2, alternative name MIP-2) concentrations in the
cellular supernatant were quantitated using murine
ELISA development kits (Peprotech, NJ, USA). Briefly,
BV-2 and PMM were seeded in triplicate onto 12-well
and poly-D-lysine coated 24-well plates at a density of
1 × 105 and 2.5 × 105 cells per well, respectively. After
serum starvation (o/n), cells were incubated in serum-
free medium, containing LPA in the absence or presence
of BrP-LPA or TCLPA5 for the indicated times. For each
time point, the supernatants were collected and kept at
−70 °C until further use. The assays were performed ac-
cording to manufacturer’s instructions. The standard
curve for each ELISA was performed in triplicate. The
concentrations of the cytokines and chemokines were
determined using the external standard curve.
NO detection
iNOS activity was assessed indirectly by measuring the
accumulated total nitrate levels in the supernatant after
12, 24, and 48 h in the case of BV-2 cells and 2, 8, 24,
and 48 h in the case of primary microglia cells, using the
total nitric oxide assay kit (ENZO Life Sciences,
Switzerland). In this Griess assay, nitrate is reduced to
nitrite by means of nitrate reductase. Fifty microliters of
supernatant from each sample were processed according
to manufacturer’s protocol. A standard curve was gener-
ated in the range between 0 and 100 μM using nitrate as
standard. The total nitrate concentration per sample was
determined using the external calibration curve.
Measurement of carboxy-H2DCFDA oxidation
Intracellular reactive oxygen species (ROS) levels were
measured using the 2′,7′-dichlorofluorescin diacetate
(DCFDA) cellular ROS detection kit (Abcam, Cam-
bridge, UK). After internalization and subsequent hy-
drolysis, the redox indicator probe carboxy-H2DCFDA is
converted to carboxy-H2DCF, which in the presence of
oxidant species is oxidized to fluorescent carboxy-DCF
[46]. BV-2 and PMM were seeded in black clear bottom
96-well plates at a density of 2.5 × 104 cells per well.
Cells were allowed to adhere overnight and then incu-
bated with 20 μM DCFDA for 40 min at 37 °C in the
dark. The solution was removed and the cells were
treated with vehicle control (DMSO), LPA, or LPA plus
TCLPA5 for 0.5, 1, 3, and 6 h. Fluorescence intensity
was measured with excitation and emission wavelengths
of 485 and 535 nm, respectively.
Statistical analysis
All experiments were performed in triplicate and re-
peated at least three times. Data are presented as mean
+ SD unless otherwise stated. Statistical significance was
determined by one-way ANOVA with Bonferroni correc-
tion using GraphPad 5.0 Prism. Values of p ≤ 0.05 were
considered significantly different.
Results
LPA receptor expression in BV-2 and PMM was ana-
lyzed by qPCR. LPA2, LPA3, LPA5, and LPA6 were de-
tected in BV-2 cells. LPA1 and 4 were undetectable
(n.d.), whereas LPA3 was detected at very low copy
numbers. In PMM LPA1, 2, 4, 5 and 6 were detected.
LPA3 was undetectable (Fig. 1a). LPA6 expression was
arbitrarily set to 1. To test whether LPA receptor expres-
sion changes upon cell activation, BV-2 and primary
cells were incubated in the presence of LPA (1 μM).
After 24 h, LPA receptor expression was analyzed by
qPCR. These experiments (Fig. 1b) revealed that LPA is
without effects on LPA receptor mRNA expression in
BV-2 cells. LPA tended to decrease LPAR mRNA in
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PMM; however, these effects were statistically not sig-
nificantly different from untreated cells.
Microglia are able to change their morphology in re-
sponse to extracellular cues. Immunofluorescence studies
revealed that LPA induced morphological changes of BV-
2 (Fig. 2a) and PMM (Fig. 2b). F-actin staining (Fig. 2,
upper panels) indicated that untreated cells were unipolar
with one or more processes. After LPA treatment, the cells
increased their surface area and acquired a flat morph-
ology with more condensed actin labeling. Also the tubu-
lin stains (Fig. 2, lower panels) indicated an increase in
cell area in response to LPA treatment. Tubulin labeling
changed from a diffuse pattern in untreated BV-2 cells to
a more dense network in response to LPA. In primary
cells, tubulin staining was also more condensed and occu-
pied a larger area after LPA treatment.
Next, we evaluated the effects of LPA on BV-2
polarization by Western blot analyses to get an indica-
tion about time-dependent changes of M1/M2 marker
expression. These analyses revealed that LPA increased
the expression of iNOS and COX-2 (maximum induc-
tion at 24 h), but did not affect the M2 marker Arg-1
(Fig. 3a). As expected, stimulation of BV-2 cells with
LPS (20 ng/ml) significantly increased iNOS and COX-2
levels. In contrast, IL-4 (a polarization signal towards
M2) induced Arg-1 without affecting iNOS and COX-2
levels. IL-10 was without effect on iNOS and COX-2
levels but slightly decreased Arg-1 levels. The bar graphs
in the right panel represent densitometric evaluation of
the indicated protein bands.
Primary microglia were treated with LPA, LPS, or IL-4
and analyzed by confocal laser scanning microscopy for
COX-2 and Arg-1 immunoreactivity. LPA treatment
(1 μM, 24 h) led to increased COX-2 immunofluores-
cence that was mainly detected in cellular processes
(Fig. 3b, upper panel). LPS induced a more rounded cell
shape of PMM, and COX-2 staining was observed along
the cell periphery. COX-2 expression was unaffected by
IL-4. LPA (and LPS) treatment decreased Arg-1 staining,
which was increased in response to IL-4 (Fig. 3b, lower
panel). The bar graphs in the right panel show fluores-
cence intensities of micrographs displayed at the left.
In time-dependent studies, LPA increased iNOS fluor-
escence intensity in PMM (Fig. 3c) by 1.6-fold (24 h).
Using a double M1/M2 staining approach (COX-2 and
RELMα), we detected 2.3-fold increased fluorescence in-
tensity for COX-2 (at 48 h), while RELMα fluorescence
was reduced by 22 % (48 h). Arg-1 expression was also
reduced in response to LPA treatment (by 35 %). The
right panel shows fluorescence intensities.
We then analyzed surface marker expression by flow
cytometry in LPA-treated BV-2 cells and PMM. LPA































































































































Fig. 1 LPA receptor expression in BV-2 cells and primary murine microglia (PMM). a Gene expression was monitored by qPCR and normalized to the
housekeeping gene Hprt in BV-2 and PMM. Values are expressed as mean + SD (n = 6–9). LPA6 expression was arbitrarily set to 1. n.d. not detected.
b LPA receptor expression after treatment with 1 μM LPA for 24 h. Results are expressed as mean + SD from three independent experiments
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increased the percentage of CD40+ BV-2 cells from 7 to
20 % (Fig. 4a). LPS (20 ng/ml) increased the CD40+
population from 7 to 29 %. CD86 expression was in-
creased approx. twofold in response to LPA (12 and
24 h), while CD206+ cells were reduced from 35 to 22 %
(24 h). Primary microglia (Fig. 4b) showed a comparable
though more pronounced response: LPA increased the
percentage of CD40+ cells from 6 to 39 % (48 h), while
LPS increased CD40+ cells to 67 %. The CD86+ cell
population increased from 13 to 29 % (12 h) and then
decreased to ≈12 % (48 h). The CD206+ population was
reduced from 17 to 6 % (48 h).
Next, we determined the effect of LPA treatment on gene
expression and secretion of selected pro-inflammatory cy-
tokines and chemokines that are associated with an M1-
like microglia phenotype [47]. qPCR analyses revealed that
LPA increased transcription of Il1β, Tnfα, Il6, Ccl5, but not
Cxcl2 in BV-2 cells (Fig. 5a, left panel). In PMM, LPA in-
duced time-dependent transcription of Il1β, Tnfα, Il-6,
Ccl5, and Cxcl2.
In addition, we quantitated cytokine/chemokine con-
centrations in the cellular supernatants by ELISA. In both
cell types, LPA augmented secretion of IL-1β, TNFα, IL-6,
CCL5, and CXCL2 (Fig. 5b). In BV-2 cells, analytes were
maximally induced at 2 or 8 h post activation. In PMM,
maximal concentrations were observed between 24 (IL-
1β, TNFα, IL-6, CCL5) and 48 h (CXCL2).
To analyze the intracellular redox status, we measured
DCF fluorescence. These experiments revealed a twofold
increase of fluorescence 3 h post LPA addition in BV-2
cells (Fig. 6a, left panel). tert-Butyl hydroperoxide (tBHP;
an inducer of intracellular ROS formation) was used as
positive control (50 μM, 6 h). The DCF response was
more pronounced in PMM and time-dependently in-
creased (3.3-fold). In these cells, tBHP increased DCF
fluorescence by 5.7-fold (Fig. 6a, right panel). Nitrate
concentrations (surrogate markers for NO production
via iNOS) in LPA-treated BV-2 and PMM increased by
1.3- and 1.1-fold, respectively (Fig. 6b).
To get a more detailed picture which member(s) of
the LPA receptor family is/are responsible for signal
transmission in BV-2 and primary microglia, we used
the pan LPA receptor inhibitor BrP-LPA and the LPA5
inhibitor TCLPA5. TCLPA5 was chosen since LPA5 was
identified as a member of the microglia sensome [48].
To the best of our knowledge, no LPA6 inhibitor is cur-
rently commercially available. In BV-2 cells, BrP-LPA re-
duced LPA-induced COX2 expression (statistically not
significant) and increased Arg-1 signals (Fig. 7a, upper
panel). COX-2 activation by LPA was reduced by
TCLPA5 at both time points analyzed (Fig. 7a; lower
panel). During these experiments, LPA activation was
also performed in the presence of DMSO to account for
potential inadvertent effects mediated by the vehicle. Bar
graphs at the right show densitometry of immunoreac-
tive bands.
To confirm the involvement of LPA5 in PMM, we per-
formed immunofluorescence studies (Fig. 7b). These exper-
iments revealed the expected induction of iNOS and COX-
2 in response to LPA, while the M2 markers Arg-1 and
RELMα were decreased. In response to TCLPA5, iNOS
and COX-2 expression was significantly reduced with Arg-
1 and RELMα being unaffected. The right panel shows















































Fig. 2 LPA alters microglia morphology. Staining for F-actin and β-tubulin in a BV-2 cells and b primary murine microglia (PMM). Cells on chamber slides
were serum starved (o/n) and incubated in the absence or presence of LPA (1 μM, 24 h). After washing and incubation with primary and secondary
antibodies, cells were analyzed by confocal microscopy. Nuclei were stained with DAPI. Representative images reveal rearrangement of the cytoskeleton
following LPA treatment. Scale bar= 20 μm. Results from one representative experiment (out of two) are shown
Plastira et al. Journal of Neuroinflammation  (2016) 13:205 Page 7 of 18
ab
COX2











































































































































































































































Fig. 3 (See legend on next page.)
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Surface marker expression analyses in LPA-stimulated
BV-2 in the absence or presence of BrP-LPA and
TCLPA5 is shown in Fig. 8. CD40 expression was lower
in the presence of BrP-LPA (though not significant)
whereas CD86 levels were significantly decreased at all
time points analyzed (Fig. 8a). The percentage of CD206
+ cells was unaffected by BrP-LPA. The presence of
TCLPA5 during LPA activation significantly reduced the
CD40 and CD86 positive cell populations to baseline
levels at all time points analyzed while CD206 was un-
affected (Fig. 8b).
Cytokine secretion in response to LPA in BV-2
cells (Fig. 9a and PMM (Fig. 9b showed a general ten-















































































































Fig. 4 LPA induces a pro-inflammatory microglia phenotype. a Serum-starved BV-2 cells (o/n) were treated with 1 μM LPA for the indicated time
points. LPS (20 ng/ml) and IL-10 (40 ng/ml) were used as positive controls to induce M1- and M2-like phenotypes, respectively. Cells were stained with
PE anti-CD40, APC anti-CD86 or PE anti-CD206 and analyzed using a FACSCalibur flow cytometer. Results (six separate experiments in triplicate) are
expressed as mean + SD (*p < 0.05, **p < 0.01, *** p < 0.001; one-way ANOVA with Bonferroni correction). b Serum-starved PMM (o/n) were cultivated
in the presence of LPA (1 μM) for the indicted times. LPS was used as a positive control. Cells were stained with PE-conjugated anti-CD40, APC-
conjugated anti-CD86, or PE-conjugated anti-CD206 antibodies and analyzed using a Guava easyCyte 8 Millipore Flow Cytometer. Results from three
individual preparations (measurements performed in duplicate) are shown as mean values + SD (*p < 0.05, *** p < 0.001 compared to untreated cells;
one-way ANOVA with Bonferroni correction)
(See figure on previous page.)
Fig. 3 LPA promotes classical activation of BV-2 and primary microglia. a Serum-starved BV-2 cells were treated with BSA (0.1 %; ‘c.’), LPA (1 μM), LPS
(20 ng/ml), IL-4 (40 ng/ml), or IL-10 (40 ng/ml)], and cellular protein lysates were analysed by Western blotting. LPS, IL-4, and IL-10 were used to polarize
cells to an M1- or M2-like phenotype, respectively. One representative plot for each protein and the densitometric analysis (mean + SD; normalized to
actin) from four independent experiments is presented. Control = 0.1 % BSA. b Confocal immunofluorescence microscopy of PMM in the absence or
presence of LPA (1 μM, 24 h). LPS (20 ng/ml) and IL-4 (40 ng/ml) were used to induce an M1- or M2-like phenotype, respectively. Cells were stained
for CD11b (microglia marker) and COX-2 or Arg-1. Nuclei were counterstained with Hoechst. Scale bars= 20 μm. Results from one representative
experiment (out of two) are shown. c PMM cultured on chamber slides were incubated in the absence or presence of LPA (1 μM) for 24 and 48 h. Cells
were stained for specific inflammatory markers and nuclei were counterstained with Hoechst. The fluorescence intensity for each marker was
quantitated with ImageJ. At least 50 cells out of 3 different areas per chamber were measured in two independent experiments. The results are
presented as mean + SD (*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA with Bonferroni correction)











































































































































































































































































Fig. 5 LPA induces expression and secretion of pro-inflammatory cytokines and chemokines. a BV-2 and PMM were cultured on 24-well plates
and serum-starved (untreated) or incubated in the presence of 1 μM LPA for the indicated times. mRNA expression of different inflammatory
cytokines and chemokines was monitored by qPCR and normalized to Hprt. Data are shown as mean + SD from three independent experiments
performed in triplicate. Expression profiles were determined using the 2-ddCt method. b Serum-starved microglia cells were treated with LPA
(1 μM) for the indicated times. Murine ELISA kits were used to quantitate the concentrations of IL-1β, TNFα, IL-6, CCL5 (RANTES), and CXCL2 (MIP-
2) in the cellular supernatants. Results shown represent mean + SD from two independent experiments performed in triplicate. Data are expressed
as mean values + SD (*p < 0.05; **p < 0.01; ***p < 0.001; one-way ANOVA with Bonferroni correction)
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Secretion of all cyto-/chemokines was significantly re-
duced in BV-2 at one (TNFα, CCL5, and CXCL2) or two
(IL-1β, IL-6) time points (Fig. 9a). In contrast, TCLPA5
inhibited secretion of IL-1β, TNFα, and IL-6 but was
without effect on CCL5 and CXCL2 in PMM (Fig. 9b).
Finally, we determined the effects of TCLPA5 on ROS
and NO formation in both cell types. TCLPA5 signifi-
cantly reduced LPA-mediated DCF fluorescence at 6 h
in BV-2 and primary microglia (Fig. 10a). Nitrate con-
centrations were reduced at 48 (BV-2) and 24 h (PMM)
by TCLPA5 (Fig. 10b).
Discussion
In the present study, we provide first evidence that LPA
polarizes BV-2 and PMM towards an M1-like pheno-
type. Of note, the responses in BV-2 and primary micro-
glia were qualitatively comparable, indicating that BV-2
cells represent a suitable prescreening model. Our find-
ings might have bearings in neurological disease settings
where LPA levels are increased, e.g., in spinal cord in-
jury, traumatic brain injury, or multiple sclerosis [21].
LPA receptor profiling in the present study confirmed
low expression of the classical LPA1-3 receptors [28]
(and LPA4) but revealed high expression of LPA5 and
LPA6. All of the LPA receptors are expressed in the de-
veloping brain and expression levels vary with develop-
mental age [21]. LPA-mediated processes regulate
proliferation, microtubule-dependent interkinetic nu-
clear migration, neurite retraction, cell survival, morpho-
logical changes, and cell migration [21]. Thus, in
physiological conditions, LPA-mediated signaling con-
tributes to normal development and function of the
CNS.
However, in response to injury, LPA levels can rise sig-
nificantly in the brain and CSF [8, 17, 19, 49, 50]. LPA
levels are elevated in human (0.05 controls vs. 0.27 μM
post injury) and mouse (0.8 and 2 μM, prior vs. post in-
jury) CSF in response to traumatic brain injury [51]. In
this context, it is of importance that exogenous LPA can
fuel endogenous LPA production via an LPA3-
dependent pathway [52]. Overshooting LPA signaling
has been linked to the development of fetal hydroceph-
alus in embryonic mice, a pathophysiological process
that is ameliorated in LPA1/LPA2 double knockout ani-
mals [50]. LPA signaling is also involved in nerve injury-
triggered pain responses [53], where LPA1 [54] and
LPA5 [55] contribute via independent mechanisms.
















































































Fig. 6 LPA increases NO and ROS production in BV-2 and primary murine microglia. a The cellular redox status was determined using carboxy-
H2DCFDA. Serum-starved BV-2 cells and PMM were incubated with carboxy-H2DCFDA and treated with LPA (1 μM), and the fluorescence intensity was
quantitated. tert-Butyl hydroperoxide (TBHP) was used to induce intracellular ROS formation. Results (four independent experiments performed in
triplicate) are expressed as mean values + SD. (**p≤ 0.01; ***p < 0.001; one-way ANOVA with Bonferroni correction). b Serum-starved cells were treated
with LPA (1 μM) for the indicated time periods. The production of NO was determined by measuring nitrate concentrations. Data (three independent
experiments performed in triplicate) are presented as mean values + SD. (*p < 0.05; **p < 0.01; one-way ANOVA with Bonferroni correction)


















































































































































Fig. 7 Inhibition of LPA5 suppresses the LPA-induced pro-inflammatory phenotype in BV-2 and primary murine microglia. a Serum-starved BV-2 cells
were treated with LPA in the absence or presence of BrP-LPA (5 μM; upper panel) or TCLPA5 (5 μM; lower panel) added 2 h prior to LPA addition.
COX-2 and Arg-1 response was monitored using Western blotting. One representative plot for each protein and the densitometric analysis (mean +
SD) from four independent experiments is presented. (**p < 0.01; ***p < 0.001; #p < 0.05, inhibitor compared to LPA-treated cells; one-way ANOVA with
Bonferroni correction). b PMM were incubated in the presence of vehicle (DMSO; 'untreated'), LPA (1 μM), vehicle (DMSO) plus LPA (1 µM), or TCLPA5
(5 μM in DMSO; added 2 h prior to LPA addition) plus LPA (1 µM) for 24 h. Cells were stained for iNOS, COX-2, Arg-1, or RELMα and visualized using
confocal microscopy. Fluorescence intensity was quantitated with ImageJ. At least 50 cells out of 3 different areas per chamber were measured. Results
(three independent experiments) are presented as mean + SD (*p < 0.05; ***p < 0.001; #p < 0.05 inhibitor compared to LPA-treated cells; one-way
ANOVA with Bonferroni correction)
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not under basal conditions) are consistent with the fact
that LPA levels rise significantly in response to spinal
cord injury [8, 19]. In the contused spinal cord, paren-
chymal LPA concentrations increase from 75 to 725
pmol/mg protein (naïve vs. 3 days post injury) and con-
tribute to secondary injury manifested as demyelination
[19]. Demyelination in the injured spinal cord was (at
least in part) ascribed to LPA-activated microglia [19].
Lysophosphatidylcholine injected intrathecally is con-
verted to LPA via ATX-mediated pathways, and an
LPA3-dependent feed-forward loop induces further en-
dogenous synthesis of LPA [52]. It was suggested that
within this setting, microglia activation is responsible for
de novo LPA synthesis and concomitant development of
neuropathic pain [56]. Thus, findings of the present study
that LPA induces an M1-like microglial phenotype are
relevant to pathophysiology in the injured/diseased CNS.
Here we show that LPA induces the expression of an
M1 signature in BV-2 and primary microglia. In line
with a previous study [47], LPS induced iNOS, COX-2,
CD40, and CD86 expression. LPA treatment resulted in
the upregulation of the M1 markers iNOS, COX-2,
CD40, and CD86 and downregulation of the M2
markers CD206 (MRC1), Arg-1, and Relmα in BV-2 and
primary microglia. The transcriptional programs that
drive an LPA-mediated M1 signature are currently under
investigation. Classical M1 marker expression was ac-
companied by increased cytokine/chemokine mRNA and
protein levels as well as ROS and NO production in BV-
2 and PMM. In PMM, LPS increased iNOS and COX-2
expression as well as IL-6 release [47] in a similar man-
ner as observed here for LPA-treated BV-2 cells and
PMM. Also, the temporal expression profiles are in
agreement to what was reported for M1 marker expres-
sion in LPS-treated PMM: Gene expression of iNOS and
COX-2 was significantly elevated between 4 and 72 h,
and protein levels of IL-6 were significantly elevated over
baseline up to 72 h [47]. The 2.5-fold increase in IL-6 se-
cretion of primary microglia in response to LPA ob-
served here is in a comparable range reported for LPA-
stimulated fibroblast-like synoviocytes [57], which play
an active role in synovial inflammation and damage via
ATX/LPA-mediated pathways. iNOS is not expressed in
the healthy brain, but expression is induced in response
to inflammatory mediators like LPS or cytokines. In-
creased ROS and NO concentrations make it reasonable
to assume that, in response to iNOS upregulation, excess
NO reacts with NADPH oxidase-derived O2
−. This reac-
tion results in the formation of the highly neurotoxic
peroxynitrite (ONOO−) in BV-2 microglia [58]. It is im-
portant to note that DCF (used during the present study
to detect alterations in cellular redox balance) is not a
species-specific probe but is, in addition to H2O2, also
oxidized by hypochlorous acid (generated via the myelo-
peroxidase/H2O2/chloride system), other peroxidases,
and ONOO− [59]. ONOO− was shown to induce mito-
chondrial dysfunction in neurons [60] to damage oligo-














































































































































































































































TCLPA5 + LPADMSO + LPA
a
b
Fig. 8 LPA receptor antagonists attenuate M1 surface marker expression in BV-2 cells. Serum-starved (o/n) cells were cultivated in the presence of
vehicle, LPA (1 μM), or LPA plus a BrP-LPA (5 μM) and b TCLPA5 (5 μM) for the indicated times. Inhibitors were added 2 h prior LPA addition. Cells
were stained with PE-conjugated anti-CD40, APC-conjugated anti-CD86, or PE-conjugated anti-CD206 antibodies and analyzed using a Guava
easyCyte 8 Millipore flow cytometer. Results from four individual experiments in triplicate are shown as mean values + SD. (*p < 0.05; **p < 0.01;
***p < 0.001 compared to untreated or DMSO-treated cells; #p < 0.05; ##p < 0.01; ###p < 0.001 inhibitor compared to LPA-treated cells; one-way
ANOVA with Bonferroni correction)
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Fig. 9 (See legend on next page.)
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function [62]. Although our results suggest that LPA
stimulation leads to ROS and NO production and is po-
tentially neurotoxic, Awada and colleagues [63] have
shown that overexpression of ATX in BV-2 microglia
protects cells against H2O2-induced cell damage and
oxidative stress. The same group [64] demonstrated
ATX-mediated downregulation of cytokine production
(mRNA and protein) in LPS-stimulated BV-2 cells.
These seemingly contradictory results to the present
study might be simply due to different incubation/cul-
ture conditions: In the ATX overexpression model [63],
BV-2 cells are continuously exposed to LPA concentra-
tions that are approx. fourfold elevated over the vector
controls in contrast to the single addition used in the
present study. Although we show that exposure to a sin-
gle LPA bolus does not change LPA receptor expression
in BV-2 cells and PMM, the situation might be different
in ATX-overexpressing microglia. In terms of downregu-
lated cytokine production in ATX-overexpressing BV-2
cells, Awada et al. [64] used LPS-stimulated cells while
we studied effects of LPA on BV-2 and PMM that were
exposed only to LPA (in the absence of a co-agonist).
This is reminiscent of what was reported for periton-
eal macrophages [65]: In that study, LPA induced IL-
6 but not TNFα secretion in unstimulated macro-
phages while in LPS-stimulated cells, LPA downregu-
lated TNFα but not IL-6 production. Thus, it appears
that LPA-mediated effects depend on the cellular
(See figure on previous page.)
Fig. 9 TCLPA5 inhibits the secretion of pro-inflammatory cytokines and chemokines. a BV-2 and b PMM were cultured on 24-well plates and serum-
starved o/n. The supernatants were collected after incubation with vehicle, 1 μM LPA, or LPA plus TCLPA5 (5 μM) for the indicated times. The concen-
trations of IL-1β, TNFα, IL-6, CCL5 (RANTES), and CXCL2 (MIP-2) were quantitated by ELISA. Results shown represent mean + SD from two independent
experiments performed in triplicate (*p < 0.05; **p < 0.01; ***p < 0.001 compared to vehicle control; #p < 0.05, ##p < 0.01; ###p < 0.001 TCLPA5 compared
to LPA treated cells; one-way ANOVA with Bonferroni correction)
a
b
DMSO+LPA TCLPA5+LPA DMSO+LPA TCLPA5+LPA
DMSO+LPA TCLPA5+LPA DMSO+LPA TCLPA5+LPA











































































Fig. 10 TCLPA5 suppresses ROS and NO production. a The intracellular ROS levels generated by BV-2 and PMM were determined using carboxy-
H2DCFDA. Serum-starved BV-2 and PMM were incubated with carboxy-H2DCFDA, treated with vehicle control, LPA (1 μM), or LPA plus TCLPA5 (5 μM)
for the indicated time periods, and the fluorescence intensity was evaluated. Results (three independent experiments performed in triplicate) are pre-
sented as mean values + SD. (**p < 0.01; ***p < 0.001 compared to vehicle; #p < 0.05 compared to LPA treated cells; one-way ANOVA with Bonferroni
correction). b Serum-starved BV-2 and PMM were incubated with vehicle (DMSO), LPA (1 μM), or LPA plus TCLPA5 (5 μM) for the indicated times, and
the production of NO was determined by measuring the total nitrate concentration in the supernatants. Data (three independent experiments per-
formed in triplicate) are presented as mean values + SD. (*p < 0.05; compared to untreated cells; #p < 0.05 compared to LPA treated cells; one-way
ANOVA with Bonferroni correction)
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preactivation experience resulting in altered respon-
siveness upon rechallenge probably related to the in-
trinsic immune memory of microglia [66].
Time-dependent gene/protein expression of cytokines/
chemokines have profiles specific for an M1 or M2
microglia phenotype [47]. We observed upregulated ex-
pression of IL-1β, IL-6, Tnfα, and the immunomodula-
tory chemokines CCL5 and CXCL2 in response to LPA
treatment, findings reminiscent of what was reported for
LPS-activated PMM [47]. In particular, increased IL-1β,
IL-6, and TNFα concentrations were linked to a poor
prognosis in infants suffering from ischemic encephal-
opathy [67]. In addition, IL-1β, IL-6, TNFα, and the
chemokines CCL5 and CXCL2 (which were all upreg-
ulated by LPA in primary microglia) are implicated as
modulators of the neuroinflammatory response during
traumatic brain injury [68] where LPA levels are in-
creased [51].
To get first indications about LPA receptors that are
responsible for signal transmission in microglia, we have
performed pharmacological inhibitor studies. BrP-LPA is
a pan LPA receptor/ATX inhibitor [44] while TCLPA5 is
a specific antagonist of LPA5 [45]. Of note, both inhibi-
tors suppressed M1 marker expression in BV-2 and
PMM and attenuated LPA-stimulated cytokine secretion.
Since TCLPA5 blunted all pro-inflammatory signals, it is
conceivable that LPA5 is a major player in LPA-
dependent M1 polarization of microglia. Our findings
are in line with LPA5-mediated signaling cascades in im-
munocompetent cells including a sensome function in
microglia [48]. Using a novel chemical probe acting as
specific antagonist for LPA5, it was shown that this re-
ceptor induces Ca2+ release from LPA-stimulated BV-2
cells in response to hexadecyl-LPA [69]. In line with re-
sults of the present study, Kozian and colleagues [69]
demonstrated highest expression for LPA5 in BV-2 cells
(LPA6 is not mentioned in this article) and reported a
sub μM IC50 (730 nM) for this novel LPA5 antagonist
for Ca2+ release in 16:0 alkyl-LPA stimulated BV-2 cells.
Currently, no published data are available whether com-
mercially available TCLPA5 or the LPA5 antagonist de-
scribed in [69] crosses the blood-brain or blood-
cerebrospinal fluid barriers to foster application in CNS
disease models. In human mast cells, LPA5 is essential
for conveying signals leading to MIP-1β (CCL4) gener-
ation and secretion underlining the importance of this
signaling route as regulator of cyto- and/or chemokine
production [70].
Based on the present results (graphically summa-
rized in Fig. 11), we hypothesize that interference
with the LPA/LPA5 signaling axis might provide an
opportunity to pharmacologically shift microglia
polarization. However, the therapeutic usefulness of
such an approach has to be carefully evaluated in in
vivo studies.
Conclusions
We conclude that our data provide functional support
for a sensome function of LPA5 in BV-2 and PMM.
The present in vitro study indicates that interference
with the LPA signaling axis either at the level of LPA
synthesis (using, e.g., ATX inhibitors) or at the level
of signal transmission (LPA receptor antagonists)
could offer new means to modulate the microglia
polarization status.
Non-activated microglia cell M1-like phenotype
Fig. 11 Graphical summary of findings obtained during the present study. LPA treatment induces a unique pro-inflammatory M1-like signature in
BV-2 and PMM that is completely or partially reversed by pre-treatment with the LPA5 inhibitor TCLPA5. Data of the present study provide func-
tional evidence for the role of LPA5 as member of the microglia sensome
Plastira et al. Journal of Neuroinflammation  (2016) 13:205 Page 16 of 18
Acknowledgements
We express our thanks to Drs. Fritz Andrae and Andreas Artl (both piCHEM
Graz; http://www.pichem.at) for the help with Limulus testing and to Anja
Feiner for the expert technical support.
Funding
Financial support was provided by the Austrian Science Fund (FWF; DK-
MOLIN W1241 and DK-MCD W1226), the Medical University of Graz (support-
ing the PhD programs DK-MOLIN and DK-MCD), and BioTechMed-Graz.
Availability of data and materials
There is no data, software, databases, and application/tool available apart
from the data reported in the present study. All data is provided in the
manuscript.
Authors’ contributions
IP, EB, AH, DK, MG, and WS conceived and designed the experiments. IP, EB,
MG, HR, VBK, NK, AW, AH, SS, and KJ performed the experiments. IP, EB, MG,
AW, SS, KJ, AH, DK, and WS analyzed the data. IP, EB, EM, and WS wrote the
paper. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Institute of Molecular Biology and Biochemistry, Medical University of Graz,
Harrachgasse 21, 8010 Graz, Austria. 2BioTechMed-Graz, Graz, Austria.
3Institute of Cell Biology, Histology and Embryology, Medical University of
Graz, Graz, Austria. 4Institute of Experimental and Clinical Pharmacology,
Medical University of Graz, Graz, Austria.
Received: 21 July 2016 Accepted: 20 August 2016
References
1. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS.
Glia. 2002;40(2):133–9.
2. Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: new roles for the
synaptic stripper. Neuron. 2013;77(1):10–8. doi:10.1016/j.neuron.2012.12.023.
3. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly
dynamic surveillants of brain parenchyma in vivo. Science. 2005;308(5726):
1314–8. doi:10.1126/science.1110647.
4. Lucin KM, Wyss-Coray T. Immune activation in brain aging and
neurodegeneration: too much or too little? Neuron. 2009;64(1):110–22.
doi:10.1016/j.neuron.2009.08.039.
5. Aldskogius H. Regulation of microglia—potential new drug targets in the
CNS. Expert Opin Ther Targets. 2001;5(6):655–68.
6. Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2
microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;
11(1):98. doi:10.1186/1742-2094-11-98.
7. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid
production. Biochim Biophys Acta. 2008;1781(9):513–8. doi:10.1016/j.bbalip.
2008.06.005.
8. Ma L, Uchida H, Nagai J, Inoue M, Aoki J, Ueda H. Evidence for de novo
synthesis of lysophosphatidic acid in the spinal cord through phospholipase
A2 and autotaxin in nerve injury-induced neuropathic pain. J Pharmacol Exp
Ther. 2010;333(2):540–6. doi:10.1124/jpet.109.164830.
9. Shindou H, Hishikawa D, Harayama T, Yuki K, Shimizu T. Recent progress on
acyl CoA: lysophospholipid acyltransferase research. J Lipid Res. 2009;
50(Suppl):S46–51. doi:10.1194/jlr.R800035-JLR200.
10. Moolenaar WH, Perrakis A. Insights into autotaxin: how to produce and
present a lipid mediator. Nat Rev Mol Cell Biol. 2011;12(10):674–9.
doi:10.1038/nrm3188.
11. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al.
Autotaxin has lysophospholipase D activity leading to tumor cell growth
and motility by lysophosphatidic acid production. J Cell Biol. 2002;158(2):
227–33. doi:10.1083/jcb.200204026.
12. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, et al. Autotaxin
stabilizes blood vessels and is required for embryonic vasculature by
producing lysophosphatidic acid. J Biol Chem. 2006;281(35):25822–30.
doi:10.1074/jbc.M605142200.
13. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA,
Pradere JP, et al. Autotaxin, a secreted lysophospholipase D, is essential for
blood vessel formation during development. Mol Cell Biol. 2006;26(13):
5015–22. doi:10.1128/MCB.02419-05.
14. Fotopoulou S, Oikonomou N, Grigorieva E, Nikitopoulou I, Paparountas T,
Thanassopoulou A, et al. ATX expression and LPA signalling are vital for the
development of the nervous system. Dev Biol. 2010;339(2):451–64.
doi:10.1016/j.ydbio.2010.01.007.
15. Giganti A, Rodriguez M, Fould B, Moulharat N, Coge F, Chomarat P, et al.
Murine and human autotaxin alpha, beta, and gamma isoforms: gene
organization, tissue distribution, and biochemical characterization. J Biol
Chem. 2008;283(12):7776–89. doi:10.1074/jbc.M708705200.
16. Triebl A, Trotzmuller M, Eberl A, Hanel P, Hartler J, Kofeler HC. Quantitation
of phosphatidic acid and lysophosphatidic acid molecular species using
hydrophilic interaction liquid chromatography coupled to electrospray
ionization high resolution mass spectrometry. J Chromatogr A. 2014;1347:
104–10. doi:10.1016/j.chroma.2014.04.070.
17. Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, Leffler CW.
Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am J Phys.
1995;268(5 Pt 2):H2048–55.
18. Sun GY, Lu FL, Lin SE, Ko MR. Decapitation ischemia-induced release of free
fatty acids in mouse brain. Relationship with diacylglycerols and
lysophospholipids. Mol Chem Neuropathol. 1992;17(1):39–50.
19. Santos-Nogueira E, Lopez-Serrano C, Hernandez J, Lago N, Astudillo AM,
Balsinde J, et al. Activation of lysophosphatidic acid receptor type 1
contributes to pathophysiology of spinal cord injury. J Neurosci. 2015;35(28):
10224–35. doi:10.1523/JNEUROSCI.4703-14.2015.
20. Choi JW, Chun J. Lysophospholipids and their receptors in the central
nervous system. Biochim Biophys Acta. 2013;1831(1):20–32. doi:10.1016/j.
bbalip.2012.07.015.
21. Yung YC, Stoddard NC, Mirendil H, Chun J. Lysophosphatidic acid signaling
in the nervous system. Neuron. 2015;85(4):669–82. doi:10.1016/j.neuron.2015.
01.009.
22. Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor
nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014;171(15):3575–
94. doi:10.1111/bph.12678.
23. On NH, Savant S, Toews M, Miller DW. Rapid and reversible enhancement of
blood-brain barrier permeability using lysophosphatidic acid. J Cereb Blood
Flow Metab. 2013;33(12):1944–54. doi:10.1038/jcbfm.2013.154.
24. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1)
encodes a lysophosphatidic acid receptor expressed in neurogenic regions
of the developing cerebral cortex. J Cell Biol. 1996;135(4):1071–83.
25. Trimbuch T, Beed P, Vogt J, Schuchmann S, Maier N, Kintscher M, et al.
Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-
mediated signaling. Cell. 2009;138(6):1222–35. doi:10.1016/j.cell.2009.06.050.
26. Weiner JA, Hecht JH, Chun J. Lysophosphatidic acid receptor gene vzg-1/
lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in
the postnatal murine brain. J Comp Neurol. 1998;398(4):587–98.
27. Bernhart E, Kollroser M, Rechberger G, Reicher H, Heinemann A, Schratl P, et
al. Lysophosphatidic acid receptor activation affects the C13NJ microglia
cell line proteome leading to alterations in glycolysis, motility, and
cytoskeletal architecture. Proteomics. 2010;10(1):141–58. doi:10.1002/pmic.
200900195.
28. Moller T, Contos JJ, Musante DB, Chun J, Ransom BR. Expression and
function of lysophosphatidic acid receptors in cultured rodent microglial
cells. J Biol Chem. 2001;276(28):25946–52. doi:10.1074/jbc.M102691200.
29. Schilling T, Stock C, Schwab A, Eder C. Functional importance of Ca2
+ -activated K+ channels for lysophosphatidic acid-induced microglial
migration. Eur J Neurosci. 2004;19(6):1469–74. doi:10.1111/j.1460-9568.2004.
03265.x.
30. Muessel MJ, Harry GJ, Armstrong DL, Storey NM. SDF-1alpha and LPA
modulate microglia potassium channels through rho gtpases to regulate
cell morphology. Glia. 2013;61(10):1620–8. doi:10.1002/glia.22543.
31. Fujita R, Ma Y, Ueda H. Lysophosphatidic acid-induced membrane ruffling
and brain-derived neurotrophic factor gene expression are mediated by
Plastira et al. Journal of Neuroinflammation  (2016) 13:205 Page 17 of 18
ATP release in primary microglia. J Neurochem. 2008;107(1):152–60.
doi:10.1111/j.1471-4159.2008.05599.x.
32. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress
from lymphoid organs. Annu Rev Immunol. 2012;30:69–94. doi:10.1146/
annurev-immunol-020711-075011.
33. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. Autotaxin, an
ectoenzyme that produces lysophosphatidic acid, promotes the entry of
lymphocytes into secondary lymphoid organs. Nat Immunol. 2008;9(4):415–
23. doi:10.1038/ni1573.
34. Nakasaki T, Tanaka T, Okudaira S, Hirosawa M, Umemoto E, Otani K, et al.
Involvement of the lysophosphatidic acid-generating enzyme autotaxin in
lymphocyte-endothelial cell interactions. Am J Pathol. 2008;173(5):1566–76.
doi:10.2353/ajpath.2008.071153.
35. Knowlden S, Georas SN. The autotaxin-LPA axis emerges as a novel
regulator of lymphocyte homing and inflammation. J Immunol. 2014;192(3):
851–7. doi:10.4049/jimmunol.1302831.
36. Bai Z, Cai L, Umemoto E, Takeda A, Tohya K, Komai Y, et al. Constitutive
lymphocyte transmigration across the basal lamina of high endothelial
venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol.
2013;190(5):2036–48. doi:10.4049/jimmunol.1202025.
37. Chen R, Roman J, Guo J, West E, McDyer J, Williams MA, et al.
Lysophosphatidic acid modulates the activation of human monocyte-
derived dendritic cells. Stem Cells Dev. 2006;15(6):797–804. doi:10.1089/scd.
2006.15.797.
38. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and
disease. Nat Rev Immunol. 2011;11(11):775–87. doi:10.1038/nri3086.
39. Zhao X, Wang H, Sun G, Zhang J, Edwards NJ, Aronowski J. Neuronal
Interleukin-4 as a modulator of microglial pathways and ischemic brain
damage. J Neurosci. 2015;35(32):11281–91. doi:10.1523/JNEUROSCI.1685-15.
2015.
40. Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and
metabolic states. Br J Pharmacol. 2015. doi:10.1111/bph.13139.
41. Deierborg T. Preparation of primary microglia cultures from postnatal
mouse and rat brains. Methods Mol Biol. 2013;1041:25–31. doi:10.1007/978-
1-62703-520-0_4.
42. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods.
2001;25(4):402–8. doi:10.1006/meth.2001.1262.
43. McCall MN, McMurray HR, Land H, Almudevar A. On non-detects in qPCR
data. Bioinformatics. 2014;30(16):2310–6. doi:10.1093/bioinformatics/btu239.
44. Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology,
physiology, and pathophysiology. J Lipid Res. 2014. doi:10.1194/jlr.R046458.
45. Kozian DH, Evers A, Florian P, Wonerow P, Joho S, Nazare M. Selective non-
lipid modulator of LPA5 activity in human platelets. Bioorg Med Chem Lett.
2012;22(16):5239–43. doi:10.1016/j.bmcl.2012.06.057.
46. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage
in vivo and in cell culture: how should you do it and what do the results
mean? Br J Pharmacol. 2004;142(2):231–55. doi:10.1038/sj.bjp.0705776.
47. Chhor V, Le Charpentier T, Lebon S, Ore MV, Celador IL, Josserand J, et al.
Characterization of phenotype markers and neuronotoxic potential of
polarised primary microglia in vitro. Brain Behav Immun. 2013;32:70–85.
doi:10.1016/j.bbi.2013.02.005.
48. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, et
al. The microglial sensome revealed by direct RNA sequencing. Nat
Neurosci. 2013;16(12):1896–905. doi:10.1038/nn.3554.
49. Savaskan NE, Rocha L, Kotter MR, Baer A, Lubec G, van Meeteren LA, et al.
Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation
during development and after neurotrauma. Cell Mol Life Sci. 2007;64(2):
230–43. doi:10.1007/s00018-006-6412-0.
50. Yung YC, Mutoh T, Lin ME, Noguchi K, Rivera RR, Choi JW, et al.
Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci Transl
Med. 2011;3(99):99ra87. doi:10.1126/scitranslmed.3002095.
51. Crack PJ, Zhang M, Morganti-Kossmann MC, Morris AJ, Wojciak JM, Fleming JK,
et al. Anti-lysophosphatidic acid antibodies improve traumatic brain injury
outcomes. J Neuroinflammation. 2014;11:37. doi:10.1186/1742-2094-11-37.
52. Ma L, Uchida H, Nagai J, Inoue M, Chun J, Aoki J, et al. Lysophosphatidic
acid-3 receptor-mediated feed-forward production of lysophosphatidic acid:
an initiator of nerve injury-induced neuropathic pain. Mol Pain. 2009;5:64.
doi:10.1186/1744-8069-5-64.
53. Ueda H, Matsunaga H, Olaposi OI, Nagai J. Lysophosphatidic acid: chemical
signature of neuropathic pain. Biochim Biophys Acta. 2013;1831(1):61–73.
doi:10.1016/j.bbalip.2012.08.014.
54. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of
neuropathic pain requires lysophosphatidic acid receptor signaling. Nat
Med. 2004;10(7):712–8. doi:10.1038/nm1060.
55. Lin ME, Rivera RR, Chun J. Targeted deletion of LPA5 identifies novel roles
for lysophosphatidic acid signaling in development of neuropathic pain. J
Biol Chem. 2012;287(21):17608–17. doi:10.1074/jbc.M111.330183.
56. Ma L, Nagai J, Ueda H. Microglial activation mediates de novo
lysophosphatidic acid production in a model of neuropathic pain. J
Neurochem. 2010;115(3):643–53. doi:10.1111/j.1471-4159.2010.06955.x.
57. Zhao C, Fernandes MJ, Prestwich GD, Turgeon M, Di Battista J, Clair T, et al.
Regulation of lysophosphatidic acid receptor expression and function in
human synoviocytes: implications for rheumatoid arthritis? Mol Pharmacol.
2008;73(2):587–600. doi:10.1124/mol.107.038216.
58. Kumar A, Chen SH, Kadiiska MB, Hong JS, Zielonka J, Kalyanaraman B, et al.
Inducible nitric oxide synthase is key to peroxynitrite-mediated, LPS-induced
protein radical formation in murine microglial BV2 cells. Free Radic Biol
Med. 2014;73:51–9. doi:10.1016/j.freeradbiomed.2014.04.014.
59. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive
metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am
J Physiol Regul Integr Comp Physiol. 2004;286(3):R431–44. doi:10.1152/
ajpregu.00361.2003.
60. Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the
pathogenesis of Parkinson’s disease. Antioxid Redox Signal. 2003;5(3):319–
35. doi:10.1089/152308603322110896.
61. Baud O, Li J, Zhang Y, Neve RL, Volpe JJ, Rosenberg PA. Nitric oxide-
induced cell death in developing oligodendrocytes is associated with
mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur J
Neurosci. 2004;20(7):1713–26. doi:10.1111/j.1460-9568.2004.03616.x.
62. Ding R, Chen Y, Yang S, Deng X, Fu Z, Feng L, et al. Blood-brain barrier
disruption induced by hemoglobin in vivo: Involvement of up-regulation of
nitric oxide synthase and peroxynitrite formation. Brain Res. 2014;1571:25–
38. doi:10.1016/j.brainres.2014.04.042.
63. Awada R, Rondeau P, Gres S, Saulnier-Blache JS, Lefebvre d’Hellencourt C,
Bourdon E. Autotaxin protects microglial cells against oxidative stress. Free
Radic Biol Med. 2012;52(2):516–26. doi:10.1016/j.freeradbiomed.2011.11.014.
64. Awada R, Saulnier-Blache JS, Gres S, Bourdon E, Rondeau P, Parimisetty A, et
al. Autotaxin downregulates LPS-induced microglia activation and pro-
inflammatory cytokines production. J Cell Biochem. 2014;115(12):2123–32.
doi:10.1002/jcb.24889.
65. Fan H, Zingarelli B, Harris V, Tempel GE, Halushka PV, Cook JA.
Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-
inflammatory response: potential anti-inflammatory signaling pathways. Mol
Med. 2008;14(7-8):422–8. doi:10.2119/2007-00106.Fan.
66. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia.
Physiol Rev. 2011;91(2):461–553. doi:10.1152/physrev.00011.2010.
67. Aly H, Khashaba MT, El-Ayouty M, El-Sayed O, Hasanein BM. IL-1beta, IL-6
and TNF-alpha and outcomes of neonatal hypoxic ischemic
encephalopathy. Brain Dev. 2006;28(3):178–82. doi:10.1016/j.braindev.2005.
06.006.
68. Gyoneva S, Ransohoff RM. Inflammatory reaction after traumatic brain injury:
therapeutic potential of targeting cell-cell communication by chemokines.
Trends Pharmacol Sci. 2015;36(7):471–80. doi:10.1016/j.tips.2015.04.003.
69. Kozian DH, von Haeften E, Joho S, Czechtizky W, Anumala UR, Roux P, et al.
Modulation of hexadecyl-LPA-mediated activation of mast cells and
microglia by a chemical probe for LPA5. Chembiochem. 2016;17(9):861–5.
doi:10.1002/cbic.201500559.
70. Lundequist A, Boyce JA. LPA5 is abundantly expressed by human mast cells
and important for lysophosphatidic acid induced MIP-1beta release. PLoS
One. 2011;6(3):e18192. doi:10.1371/journal.pone.0018192.
Plastira et al. Journal of Neuroinflammation  (2016) 13:205 Page 18 of 18
